Stock Monitor: Anika Therapeutics Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Jazz Pharma PLC (NASDAQ: JAZZ). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JAZZ as the Company’s latest news hit the wire. On February 23, 2018, the Company announced enrolment of first patient in a Phase-2 clinical trial evaluating the efficacy and safety of defibrotide for the prevention of acute Graft-versus-Host-Disease (aGvHD) in adults and pediatric patients after allogeneic hematopoietic stem cell transplant (HSCT). The defibrotide clinical trial will be conducted across 60 medical centers in the United States, Canada, and European Union. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Anika Therapeutics, Inc. (NASDAQ: ANIK), which also belongs to the Healthcare sector as the Company Jazz Pharma. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=ANIK
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Jazz Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=JAZZ
Defibrotide Phase-2 Clinical Trial
The Phase-2 clinical trial is a prospective, randomized, open-label study of the efficacy and safety of defibrotide added to standard of care immunoprophylaxis for the prevention of aGvHD, compared to the standard of care alone. Jazz will enroll approximately 150 adult and pediatric patients who have undergone allogeneic HSCT from an unrelated donor. The primary endpoint is cumulative incidence of Grade B-D aGvHD by day +100 post-allogeneic HSCT. The trial is anticipated to begin in March 2018 and complete in January 2020.
Phase-2 Trial Complements Ongoing Phase-3 Trial Evaluating Defibrotide for Prevention of VOD in Patients Undergoing HSCT
This defibrotide Phase-2 trial complements the Company’s ongoing Phase-3 clinical trial evaluating defibrotide for prevention of hepatic veno-occlusive disease (VOD) in high-risk adult and pediatric patients undergoing HSCT. In January 2017, Jazz enrolled first patient in a Phase-3 clinical trial comparing the efficacy and safety of defibrotide versus best supportive care (BSC) in the prevention of hepatic VOD in adult and pediatric patients undergoing HSCT who are at high risk or at very high risk of developing VOD.
HSCT is an aggressive, potentially curative procedure to treat patients with malignant and non-cancerous hematologic disorders such as leukemia, lymphoma and aplastic anemia, and congenital immunodeficiency and autoimmune disorders. VOD is a rare complication of HSCT is an early and life-threatening complication affecting the sinusoidal endothelial cells of the liver, which can typically occur within the first 21 days following HSCT.
About Acute Graft-versus-Host-Disease (aGvHD)
GvHD is a life-threatening complication of HSCT that might occur after an allogeneic transplant. In GvHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign, and the donated cells/bone marrow attack the body, leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus, and GI tract.
About Defitelio®
Defitelio® is indicated for the treatment of adult and pediatric patients with hepatic (VOD), also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following HSCT. The most common side effects of Defitelio® are decreased blood pressure, diarrhea, vomiting, nausea, and nose bleeds. Defitelio® is not approved for the treatment of prevention of GvHD or prevention of VOD.
In the US, Defitelio® injection 80mg/mL received FDA marketing approval in March 2016 for the treatment of adult and pediatric patients with hepatic VOD with renal or pulmonary dysfunction following HSCT and is the first and only FDA-approved therapy for patients with this rare, potentially fatal complication. In October 2013, the European Commission granted marketing authorization to Defitelio under exceptional circumstances for the treatment of severe VOD in patients undergoing HSCT therapy. It is the first and only approved treatment in Europe for severe VOD.
About Jazz Pharmaceuticals PLC
Jazz Pharma is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products in the areas of sleep, hematology/oncology, and pain that address unmet medical needs. Founded in 2003 and headquartered in Dublin, Ireland, the Company has US offices in Palo Alto, California and Philadelphia, Pennsylvania, and in various other locations in Europe.
Stock Performance Snapshot
February 26, 2018 – At Monday’s closing bell, Jazz Pharma’s stock slightly dropped 0.01%, ending the trading session at $147.44.
Volume traded for the day: 390.70 thousand shares.
Stock performance in the previous three-month period – up 6.81%; and past twelve-month period – up 8.32%; and year-to-date – up 9.50%
After yesterday’s close, Jazz Pharma’s market cap was at $8.66 billion.
Price to Earnings (P/E) ratio was at 23.83.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.0% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
ReleaseID: 490820